CN106632615B - Process for extracting vasopressin solution - Google Patents
Process for extracting vasopressin solution Download PDFInfo
- Publication number
- CN106632615B CN106632615B CN201610904028.7A CN201610904028A CN106632615B CN 106632615 B CN106632615 B CN 106632615B CN 201610904028 A CN201610904028 A CN 201610904028A CN 106632615 B CN106632615 B CN 106632615B
- Authority
- CN
- China
- Prior art keywords
- solution
- vasopressin
- column
- acetic acid
- collecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention discloses a process for extracting a vasopressin solution. Comprises the steps of raw material extraction, protein removal, resin exchange, ultrafiltration, preparative high-performance liquid purification and the like. The invention adopts a process combining a plurality of separation and purification means, directly separates and purifies the animal pituitary to obtain the vasopressin, has cheap and easily obtained raw materials, and high yield and purity of the prepared product, has the advantages of simple operation, environmental protection, short production period, lower production cost and the like, and is suitable for large-scale industrial production.
Description
Technical Field
The invention relates to a biological extraction method of a medicinal raw material of vasopressin, belongs to the field of bioengineering, and particularly relates to an extraction process of a vasopressin solution.
Background
Vasopressin, also known as vasopressin, an antidiuretic hormone, is a 9-peptide hormone secreted by the neurons of the supraoptic and paraventricular nuclei of the hypothalamus and has the molecular formula: C43H67N15O12S2, molecular weight: 1050.22, released after reaching the posterior pituitary of the neurohypophysis via the hypothalamic-pituitary tract. The main function of the medicine is to improve the permeability of the distal convoluted tubule and the collecting pipe to water and promote the absorption of water, and the medicine is a key regulating hormone for concentrating and diluting urine. Is mainly used for treating diabetes insipidus and esophageal variceal bleeding.
There is no report of using a biological extraction method to prepare the vasopressin, and there is a report that the purity of the synthesized vasopressin by preparative high performance liquid purification can reach more than 95%, but the yield is only about 20%.
Disclosure of Invention
The invention aims to find a process route, which can improve the product yield and the product purity. The purification and separation are carried out by adopting the means of combining the technologies of resin exchange, ultrafiltration, preparative high-performance liquid purification and the like, thereby solving the problem.
In order to realize the purpose of the invention, the invention adopts the following technical scheme:
a process for extracting a vasopressin solution comprises the following specific steps:
the method comprises the steps of raw material extraction: adding acetic acid into posterior pituitary powder, stirring, extracting, and filtering; adding acetic acid into the filter cake again, stirring, extracting, and filtering; mixing the two filtrates;
the method comprises the following steps: stirring and heating the solution to a certain temperature, preserving the heat for a period of time, and cooling to room temperature;
the resin exchange: balancing an ion exchange resin column by using a balancing solution (adding acid into a 1 multiplied by 10 < -4 > mol/L NaOH solution to adjust the pH value), then eluting, collecting eluent, carrying out ultraviolet detection on the eluent at 280nm, collecting the boost element when the light absorption value is increased at the original light absorption value, continuously adjusting the pH value of the collection solution by using acid while collecting the boost element, and stopping collection when the light absorption value is reduced to 0.4;
fourthly, ultra-filtration: ultrafiltering the collected vasopressin with ultrafilter, and collecting filtrate;
fifthly, carrying out rough separation and purification on the preparative high-performance liquid phase: filtering the filtrate obtained in the step four by using a 0.45-micrometer filter membrane, and then performing coarse separation and purification by using a preparative high performance liquid chromatograph, wherein the method comprises the following specific steps of: 5a, balancing a preparation column; step 5b, sample loading of the booster element solution subjected to ultrafiltration in the step four; 5c, balancing and preparing the column; eluting the sample by using a mobile phase, and collecting the separated and purified crude liquid;
sixthly, preparative high-efficiency liquid phase refining: diluting the booster element solution in the step fifthly, and then refining and purifying by using a preparative high performance liquid chromatograph, wherein the steps specifically comprise: 6a, balancing a preparation column; 6b, loading the diluted booster solution; 6c, balancing and preparing the column; eluting with mobile phase, performing analytical high performance liquid tracking measurement, and collecting peak;
concentration of the ears: concentrating the refined vasopressin solution under reduced pressure by a rotary evaporator, concentrating to below 2/3 of the original volume, adding an ethanol solution, shaking uniformly, then continuously concentrating to below 2/3 of the original volume, then adding the ethanol solution, shaking uniformly, then continuously concentrating to below 2/3 of the original volume, collecting the concentrated vasopressin solution, washing the concentrated round-bottom flask with a proper amount of water for injection for three times, merging the solution into the concentrated solution, and uniformly mixing to obtain the vasopressin solution.
Preferably, the concentration of the acetic acid solution in the first step is 0.2-0.3%; the amount of the added acetic acid solution is 20-30 mL/g of posterior pituitary dry powder; the extraction temperature is 45-55 ℃; the extraction time is 10-20 min.
The heating temperature in the preferable step is 95-100 ℃; the heat preservation time is 10-20 min.
Preferably, in the step three, the acid used for regulating the pH in the preparation of the equilibrium solution is acetic acid, and the pH value is regulated to 3.5-4.5; eluting with 0.1-0.3M sodium chloride solution; and in the process of collecting the vasopressin, the acid used for adjusting the pH value is acetic acid, and the pH value is adjusted to be 3.5-4.0.
Preferably, the ultrafiltration membrane in step four has a molecular weight cut-off of 10000 dalton.
Preferably, the preparation chromatographic column in the step fifthly is a C18 column; the mobile phase is as follows: 0.2M triethylamine phosphate buffer solution-acetonitrile (80-90: 20-10); the detection wavelength is 280 nm; the equilibration solutions for the equilibration preparation columns in steps 5a and 5c were both 0.2M triethylamine phosphate buffer.
Preferably, preparing a chromatographic column as a C18 column; the mobile phase is as follows: 0.5% acetic acid solution-acetonitrile (ratio is 75-85: 25-15); the detection wavelength is 280 nm; the equilibration solutions for the equilibration preparation columns in steps 6a and 6c were both 2% acetic acid solutions.
Preferably, the water bath temperature in the step-quieting concentration process is 38-40 ℃, the vacuum pressure is 0.07-0.10 MPa, and the concentration of the added ethanol solution is 95%.
Has the advantages that:
the invention adopts a process combining a plurality of separation and purification means, directly separates and purifies the animal pituitary to obtain the vasopressin, the obtained product can ensure that the yield reaches more than 75 percent, and simultaneously the purity of the product can also reach more than 98 percent. The raw materials used are cheap and easy to obtain, and organic reagents such as acetone, ethanol and the like used in the process can be recycled. The process has the advantages of simple operation, environmental protection, short production period, lower production cost and the like, and is suitable for large-scale industrial production.
Detailed Description
The present invention is further explained by the following examples, which are not intended to limit the present invention in any way.
Example 1
Weighing 1000g of posterior pituitary powder, adding 20L of 0.2% acetic acid solution into the posterior pituitary powder for the first time, stirring at 45 ℃ for 10min, filtering to obtain filtrate and filter cake, adding 10L of 0.2% acetic acid solution into the filter cake, stirring at 45 ℃ for 10min to obtain filtrate, and mixing the two filtrates. The filtrate is stirred and heated to 95 ℃, and is cooled to room temperature after heat preservation for 10 min. Balancing weak acid type ion exchange resin column with balance liquid with pH of 3.5, eluting with 0.1M sodium chloride solution through balanced ion column, collecting eluate, performing ultraviolet detection on the eluate at 280nm, collecting booster element when the light absorption value rises, continuously adjusting pH of the collected liquid with acid to about 3.5 while collecting booster element, and stopping collection when the light absorption value is reduced to 0.4. The collected vasopressin solution was passed through an ultrafilter having a throttling molecular weight of 10000 Dalton, and the filtrate was collected. Filtering the filtrate with 0.45 μm filter membrane, and performing coarse separation and purification with preparative high performance liquid phase, wherein the chromatographic conditions are as follows: a chromatographic column: c18 column, detection wavelength: 280nm, mobile phase: 0.2M triethylamine phosphate buffer/acetonitrile (80/20), and the crude separation and purification specifically comprises: a. balancing: preparing a column by using 1-1.5 column volume balances of 0.2M triethylamine phosphate buffer solution; b. loading: loading the filtered vasopressin solution; c. balancing: preparing a column by using 1 column volume balance of 0.2M triethylamine phosphate buffer solution; d. and (3) elution: the sample was eluted with a mobile phase of 0.2M triethylamine phosphate buffer/acetonitrile (80/20) and the crude fractions were collected for isolation and purification. Refining by using preparative high performance liquid chromatography, wherein the chromatographic conditions are as follows: filling material: c18, detection wavelength: 280nm, mobile phase: 0.5% acetic acid/acetonitrile (ratio 75/25), including in particular: a. balancing: preparing a column by balancing with 2% acetic acid solution; b. loading: loading the diluted booster element solution; c. balancing: equilibrating the preparative column with 2% acetic acid solution, and then equilibrating the preparative column with 0.5% acetic acid solution for about 1 column volume; (ii) a d. And (3) elution: eluting with mobile phase, performing analytical high performance liquid tracking measurement, and collecting integrated peak. And finally, concentrating the refined vasopressin solution by a rotary evaporator under reduced pressure, wherein the water bath temperature is 38 ℃, the vacuum pressure is 0.10MPa, when the solution is concentrated to 2/3 of the original volume, adding 95% of ethanol solution, shaking up, then continuously concentrating to 2/3 of the original volume, then adding the ethanol solution, shaking up, then continuously concentrating to 2/3 of the original volume, collecting the concentrated vasopressin solution, washing the concentrated round-bottom flask with a proper amount of water for injection for three times, merging the solution into the concentrated solution, and uniformly mixing to obtain 360ml of vasopressin solution, wherein the purity is 98.6%, and the yield is 75.6% by detection.
Example 2
Weighing 800g of posterior pituitary powder, adding 20L of 0.25% acetic acid solution into the posterior pituitary powder for the first time, stirring at 50 ℃ for 15min, filtering to obtain filtrate and filter cake, adding 12L of 0.25% acetic acid solution into the filter cake, stirring at 50 ℃ for 15min to obtain filtrate, and mixing the two filtrates. The filtrate is stirred and heated to 98 ℃, kept warm for 15min and then cooled to room temperature. Balancing a weak acid type ion exchange resin column by using a balance liquid with the pH value of 4.0, eluting by using a sodium chloride solution with the concentration of 0.2M through the well-balanced ion column, collecting eluent, carrying out ultraviolet detection on the eluent at 280nm, collecting the boost element when the light absorption value is increased, continuously adjusting the pH value of the collection liquid to be about 3.8 by using acid while collecting the boost element, and stopping collection when the light absorption value is reduced to 0.4. The collected vasopressin solution was passed through an ultrafilter having a throttling molecular weight of 10000 Dalton, and the filtrate was collected. Filtering the filtrate with 0.45 μm filter membrane, and performing coarse separation and purification with preparative high performance liquid phase, wherein the chromatographic conditions are as follows: a chromatographic column: c18 column, detection wavelength: 280nm, mobile phase: 0.2M triethylamine phosphate buffer/acetonitrile (85/15), and the crude separation and purification specifically comprises: a. balancing: preparing a column by using 1-1.5 column volume balances of 0.2M triethylamine phosphate buffer solution; b. loading: loading the filtered vasopressin solution; c. balancing: preparing a column by using 1 column volume balance of 0.2M triethylamine phosphate buffer solution; d. and (3) elution: the sample was eluted with a mobile phase of 0.2M triethylamine phosphate buffer/acetonitrile (85/15) and the crude fractions were collected for isolation and purification. Refining by using preparative high performance liquid chromatography, wherein the chromatographic conditions are as follows: filling material: c18, detection wavelength: 280nm, mobile phase: 0.5% acetic acid solution/acetonitrile (ratio 80/20), including in particular: a. balancing: preparing a column by balancing with 2% acetic acid solution; b. loading: loading the diluted booster element solution; c. balancing: equilibrating the preparative column with 2% acetic acid solution, and then equilibrating the preparative column with 0.5% acetic acid solution for about 1 column volume; d. and (3) elution: eluting with mobile phase, performing analytical high performance liquid tracking measurement, and collecting integrated peak. And finally, concentrating the refined vasopressin solution by a rotary evaporator under reduced pressure, wherein the water bath temperature is 39 ℃, the vacuum pressure is 0.09MPa, when the refined vasopressin solution is concentrated to 2/3 of the original volume, adding 95% of ethanol solution, shaking up, then continuously concentrating to 1/3 of the original volume, adding the ethanol solution, shaking up, then continuously concentrating to 2/3 of the original volume, collecting the concentrated vasopressin solution, washing the concentrated round-bottom flask with a proper amount of water for injection for three times, merging the solution into the concentrated solution, and uniformly mixing to obtain 270ml of the vasopressin solution, wherein the purity of the solution is 99.0% through detection. The yield thereof was found to be 75.9%.
Example 3
Weighing 600g of posterior pituitary powder, adding 18L of 0.3% acetic acid solution into the posterior pituitary powder for the first time, stirring at 55 ℃ for 20min, filtering to obtain filtrate and filter cake, adding 12L of 0.3% acetic acid solution into the filter cake, stirring at 55 ℃ for 20min to obtain filtrate, and mixing the two filtrates. The filtrate is stirred and heated to 100 ℃, and is cooled to the room temperature after heat preservation for 20 min. Balancing a weak acid type ion exchange resin column by using a balance liquid with the pH value of 4.5, eluting by using a sodium chloride solution with the concentration of 0.3M through the well-balanced ion column, collecting eluent, carrying out ultraviolet detection on the eluent at 280nm, collecting the boost element when the light absorption value is increased, continuously adjusting the pH value of the collection liquid to be about 4.0 by using acid while collecting the boost element, and stopping collection when the light absorption value is reduced to 0.4. The collected vasopressin solution was passed through an ultrafilter having a throttling molecular weight of 10000 Dalton, and the filtrate was collected. Filtering the filtrate with 0.45 μm filter membrane, and performing coarse separation and purification with preparative high performance liquid phase, wherein the chromatographic conditions are as follows: a chromatographic column: c18 column, detection wavelength: 280nm, mobile phase: 0.2M triethylamine phosphate buffer/acetonitrile (85/15), and the crude separation and purification specifically comprises: a. balancing: preparing a column by using 1-1.5 column volume balances of 0.2M triethylamine phosphate buffer solution; b. loading: loading the filtered vasopressin solution; c. balancing: preparing a column by using 1 column volume balance of 0.2M triethylamine phosphate buffer solution; d. and (3) elution: the sample was eluted with a mobile phase of 0.2M triethylamine phosphate buffer/acetonitrile (90/10) and the crude fractions were collected for isolation and purification. Refining by using preparative high performance liquid chromatography, wherein the chromatographic conditions are as follows: filling material: c18, detection wavelength: 280nm, mobile phase: 0.5% acetic acid solution/acetonitrile (ratio 85/15), including in particular: a. balancing: preparing a column by balancing with 2% acetic acid solution; b. loading: loading the diluted booster element solution; c. balancing: preparing a column by balancing with 2% acetic acid solution; equilibrating the preparative column with 0.5% acetic acid solution for about 1 column volume; d. and (3) elution: eluting with mobile phase, performing analytical high performance liquid tracking measurement, and collecting integrated peak. And finally, concentrating the refined vasopressin solution by a rotary evaporator under reduced pressure, wherein the water bath temperature is 40 ℃, the vacuum pressure is 0.07MPa, when the refined vasopressin solution is concentrated to 2/3 of the original volume, adding 95% of ethanol solution, shaking up, then continuously concentrating to 2/3 of the original volume, adding the ethanol solution, shaking up, then continuously concentrating to 2/3 of the original volume, collecting the concentrated vasopressin solution, washing the concentrated round-bottom flask with a proper amount of water for injection for three times, merging the solution into the concentrated solution, and uniformly mixing to obtain 200ml of the vasopressin solution, wherein the purity is 98.8% and the yield is 76.1% by detection.
Claims (4)
1. A process for extracting a vasopressin solution comprises the following specific steps:
the method comprises the steps of raw material extraction: adding acetic acid into posterior pituitary powder, stirring, extracting, and filtering; adding acetic acid into the filter cake again, stirring, extracting, and filtering; mixing the two filtrates;
the method comprises the following steps: stirring and heating the solution to 95-100 ℃, preserving the heat for 10-20 min, and cooling to room temperature;
the resin exchange: firstly using 1X 10-4Adding acid into mol/L NaOH solution to adjust the pH value to be used as balance liquid to balance a weak acid type ion exchange resin column, then eluting with 0.1-0.3M sodium chloride solution, collecting eluent, carrying out ultraviolet detection on the eluent at 280nm, wherein the light absorption value is at the original valueCollecting the boost element when the light absorption value rises, continuously adjusting the pH value of the collected liquid with acid while collecting the boost element, and stopping collecting when the light absorption value is reduced to 0.4;
fourthly, ultra-filtration: ultrafiltering the collected vasopressin with ultrafilter, intercepting the molecular weight with ultrafilter membrane to 10000 Dalton, and collecting filtrate;
fifthly, carrying out rough separation and purification on the preparative high-performance liquid phase: filtering the filtrate obtained in the step four by using a 0.45-micrometer filter membrane, and then performing coarse separation and purification by using a preparative high performance liquid chromatograph, wherein the method comprises the following specific steps of: 5a, balancing a preparation column; step 5b, sample loading of the booster element solution subjected to ultrafiltration in the step four; 5c, balancing and preparing the column; eluting the sample by using a mobile phase, and collecting the separated and purified crude liquid;
sixthly, preparative high-efficiency liquid phase refining: diluting the booster element solution in the step fifthly, and refining and purifying by using a preparative high performance liquid chromatograph, wherein the refining step specifically comprises: 6a, balancing a preparation column; 6b, loading the diluted booster solution; 6c, balancing and preparing the column; eluting with a mobile phase, and collecting the integrated sub-peak;
concentration of the ears: concentrating the refined vasopressin solution under reduced pressure by a rotary evaporator, concentrating to below 2/3 of the original volume, adding an ethanol solution, shaking up, then continuously concentrating to below 2/3 of the original volume, then adding the ethanol solution, shaking up, then continuously concentrating to below 2/3 of the original volume, collecting the concentrated vasopressin solution, washing the concentrated round-bottomed flask with water for injection for three times, merging the water into the concentrated solution, and uniformly mixing to obtain a vasopressin solution;
the preparation chromatographic column in the step fifthly is a C18 column; the mobile phase is as follows: 0.2M triethylamine phosphate buffer-acetonitrile, wherein triethylamine phosphate buffer: the proportion of acetonitrile is 80-90: 20-10 parts of; the detection wavelength is 280 nm; the equilibrium solution for the equilibrium preparation columns in steps 5a and 5c is 0.2M triethylamine phosphate buffer solution;
the preparative chromatographic column in the step sixteenth is a C18 column; the mobile phase is as follows: 0.5% acetic acid solution-acetonitrile, wherein acetic acid solution: the proportion of acetonitrile is 75-85: 25-15; the detection wavelength is 280 nm; the equilibration solutions for the equilibration preparation columns in steps 6a and 6c were both 2% acetic acid solutions.
2. The process for extracting a solution of vasopressin according to claim 1, characterized in that the concentration of the acetic acid solution in the step of mixing is 0.2% -0.3%; the amount of the acetic acid solution added for the first time is 20-30 mL/g of posterior pituitary dry powder; the amount of the acetic acid solution added for the second time is 10-20 mL/g of posterior pituitary dry powder; the extraction temperature is 45-55 ℃.
3. The extraction process of the vasopressin solution as claimed in claim 1, wherein the step three is that the acid used for adjusting the pH in the preparation of the equilibrium solution is acetic acid, and the pH value is adjusted to 3.5-4.5; eluting with 0.1-0.3M sodium chloride solution; the acid used for adjusting the pH value in the process of collecting the vasopressin is acetic acid, and the pH value is adjusted to be 3.5-4.0.
4. The process for extracting a vasopressin solution according to claim 1, wherein the water bath temperature in the step-wise vacuum concentration is 38 to 40 ℃, the vacuum pressure is 0.07 to 0.10MPa, and the concentration of the added ethanol solution is 95%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610904028.7A CN106632615B (en) | 2016-10-18 | 2016-10-18 | Process for extracting vasopressin solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610904028.7A CN106632615B (en) | 2016-10-18 | 2016-10-18 | Process for extracting vasopressin solution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106632615A CN106632615A (en) | 2017-05-10 |
| CN106632615B true CN106632615B (en) | 2021-01-15 |
Family
ID=58855403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610904028.7A Active CN106632615B (en) | 2016-10-18 | 2016-10-18 | Process for extracting vasopressin solution |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106632615B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113288917B (en) * | 2021-05-12 | 2023-03-07 | 康普药业股份有限公司 | Preparation method of posterior pituitary extracting solution |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014210399A1 (en) * | 2013-06-26 | 2014-12-31 | Martin-Protean Llc | Measurement of oxytocin and vasopressin |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102190706B (en) * | 2011-04-07 | 2013-06-12 | 江苏省农业科学院 | Loach protein antihypertensive peptide and preparation method thereof |
| CN102166226A (en) * | 2011-04-19 | 2011-08-31 | 安徽宏业药业有限公司 | Production process of posterior pituitary solution |
| CN102250218B (en) * | 2011-06-28 | 2014-03-19 | 杭州华津药业股份有限公司 | Method for hydrogen-bonding adsorption purification of oxytocin by using agarose comprising beta-cyclodextrin ligand |
| CN102286078A (en) * | 2011-07-13 | 2011-12-21 | 中国药科大学 | Method for preparing polypeptide HM-3 |
| CN103087152B (en) * | 2013-01-17 | 2014-12-10 | 南京新百药业有限公司 | Extraction process of oxytocin solution |
| CN103276039A (en) * | 2013-05-23 | 2013-09-04 | 华南理工大学 | Antioxidative peptide and preparation method for same |
| CN103980351B (en) * | 2014-05-27 | 2016-05-18 | 上海第一生化药业有限公司 | The preparation method of pitressin, pitressin tannate |
| CN104450839B (en) * | 2014-11-05 | 2017-06-13 | 哈尔滨商业大学 | The preparation method of the rice bran protein peptide with ACE inhibitory activity |
-
2016
- 2016-10-18 CN CN201610904028.7A patent/CN106632615B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014210399A1 (en) * | 2013-06-26 | 2014-12-31 | Martin-Protean Llc | Measurement of oxytocin and vasopressin |
Non-Patent Citations (1)
| Title |
|---|
| Purification of Oxytocin and Vasopressin by Way of a Protein Complex;R ACHER，A LIGHT等;《J Biol Chem.》;19580731;第116-120页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106632615A (en) | 2017-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101372492B (en) | Method for preparing high-purity moxidectin | |
| US20150203530A1 (en) | Method for isolating and purifying recombinant human serum albumin from transgenic rice grain | |
| CN110835297A (en) | Method for extracting multiple active substances from waste liquid of ginkgo leaf extract production | |
| CN111039762B (en) | Method for purifying cannabidiol | |
| CN104529755A (en) | Method for separating alpha-ketoglutaric acid from conversion solution | |
| CN101787071A (en) | Purification method of vapreotide | |
| CN109438561B (en) | Purification method of triptorelin | |
| CN104098637B (en) | A kind of method of purification feldamycin | |
| TWI488862B (en) | Separation and Purification of Cyclohexyl Compounds and Their Salts | |
| CN106632615B (en) | Process for extracting vasopressin solution | |
| CN101260138B (en) | Highly effective separation purification method for polygalic acid and tenuigenin | |
| CN103058871A (en) | Separation and purification method of tobacco chlorogenic acid | |
| CN108003211A (en) | A kind of method of quick separating ganoderic acid in accessory substance from ganoderma lucidum | |
| CN109400566B (en) | Method for extracting and separating high-purity amentoflavone from Selaginella plant | |
| CN105287690A (en) | Bilberry extract and preparation method thereof | |
| CN104987952B (en) | Method for extracting volatile oil and salidroside from rhodiola rosea whole plant | |
| CN107056913A (en) | A kind of method for preparing melittin | |
| CN101683332A (en) | high purity scutellarin salt bulk drug and preparation method thereof | |
| CN111437284B (en) | Sodium aescinate pharmaceutical composition and preparation method thereof | |
| CN101073666B (en) | Method for producing kallidin proenzyme raw-material medicine | |
| CN106554379A (en) | A kind of preparation method of yellow pipe Gentiopicroside from Gentiana macrophylla Pall | |
| CN105732797A (en) | Purification method for urinary gonadotropin | |
| RU2349331C1 (en) | Method of obtaining dihydroquercetin | |
| CN116903703A (en) | Purification method of daptomycin | |
| CN111233944B (en) | High performance liquid phase method for simultaneously preparing and separating four lignans components |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |